MCK - McKesson Corporation
| Previous Close | 130.15 |
| Open | 130.62 |
| Bid | 131.24 x 800 |
| Ask | 131.38 x 200 |
| Day's Range | 130.09 - 131.85 |
| 52 Week Range | 117.19 - 178.86 |
| Volume | 669,412 |
| Avg. Volume | 1,535,141 |
| Market Cap | 25.565B |
| Beta (3Y Monthly) | 1.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.85 |
| Earnings Date | Jan 30, 2019 - Feb 4, 2019 |
| Forward Dividend & Yield | 1.56 (1.19%) |
| Ex-Dividend Date | 2018-11-30 |
| 1y Target Est | 143.15 |
Markit•4 hours agoSee what the IHS Markit Score report has to say about McKesson Corp.
McKesson Corp NYSE:MCK
- ACCESSWIRE•2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of McKesson Corporation - MCK
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / Pomerantz LLP is investigating claims on behalf of investors of McKesson Corporation ("McKesson" or the "Company") (MCK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether McKesson and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- GlobeNewswire•5 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of McKesson Corporation - MCK
Pomerantz LLP is investigating claims on behalf of investors of McKesson Corporation (“McKesson” or the “Company”) (NYSE: MCK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On this news, McKesson’s stock price fell $12.55 per share, or roughly 8.3%, to close at $138.55 per share on January 26, 2017.
- ACCESSWIRE•5 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against McKesson Corporation (MCK) and Lead Plaintiff Deadline: December 26, 2018
NEW YORK, NY / ACCESSWIRE / November 9, 2018 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against McKesson Corporation ("McKesson" or the ...
- Business Wire•6 days ago
CURRENT SHAREHOLDERS: Zamansky LLC Investigates McKesson (MCK) for Potential Breaches of Fiduciary Duties
Zamansky LLC announces that it is investigating McKesson Corporation (MCK) (“McKesson” or the “Company”) for potential breaches of fiduciary duties by its senior officers and board of directors. If you are a shareholder of McKesson who still holds your shares, please contact our firm for information. It has recently emerged from public filings that McKesson has been targeted in a price-fixing investigation by several state attorney generals.
American City Business Journals•6 days agoWill the Bay Area quietly lose another Fortune 500 headquarters to Texas?
San Francisco quietly lost the headquarters of Core-Mark Holding Co., which disclosed on an earnings call that it's moving its headquarters to Dallas next year. Will this health care company follow?
- Thomson Reuters StreetEvents•7 days ago
Edited Transcript of MCK earnings conference call or presentation 25-Oct-18 12:00pm GMT
Q2 2019 McKesson Corp Earnings Call
- ACCESSWIRE•9 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of McKesson Corporation - MCK
NEW YORK, NY / ACCESSWIRE / November 5, 2018 / Pomerantz LLP is investigating claims on behalf of investors of McKesson Corporation ("McKesson" or the "Company") (MCK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether McKesson and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- GlobeNewswire•12 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of McKesson Corporation - MCK
Pomerantz LLP is investigating claims on behalf of investors of McKesson Corporation (“McKesson” or the “Company”) (MCK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext.
- ACCESSWIRE•12 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against McKesson Corporation (MCK) and Lead Plaintiff Deadline: December 26, 2018
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against McKesson Corporation (''McKesson'' or the ''Company'') ...
- The Wall Street Journal•13 days ago
[$$] Longtime McKesson CEO to Step Down
will retire next year, capping a 17-year reign in which he helped build one of the country’s largest pharmaceutical wholesalers despite weathering shareholder criticism over his compensation and handling of the opioid crisis. , McKesson’s lead independent director, will take over as chairman of the board, the company said Thursday. “This is the right time to turn the leadership reins over to the next generation and no one is better equipped than Brian to lead McKesson into the future,” Mr. Hammergren said in a written statement.
- Business Wire•13 days ago
John Hammergren Announces Retirement; Brian Tyler to Become McKesson’s CEO and Edward Mueller to Chair Board
McKesson Corporation (MCK) today announced that John H. Hammergren, chairman and chief executive officer (CEO), has decided to retire, effective March 31, 2019. McKesson’s Board of Directors has unanimously selected Brian Tyler, 51, currently president and chief operating officer (COO), to succeed Hammergren as CEO, effective April 1, 2019. Tyler will also remain as president.
- ACCESSWIRE•14 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of McKesson Corporation - MCK
NEW YORK, NY / ACCESSWIRE / October 31, 2018 / Pomerantz LLP is investigating claims on behalf of investors of McKesson Corporation ("McKesson" or the "Company") (MCK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether McKesson and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
- Morningstar•14 days ago
McKesson Is Deeply Discounted
Despite the tumult that has engulfed its operating environment, we believe McKesson MCK will remain a key healthcare player and be able to produce outsize economic value. Its fiscal second quarter reflected a stabilization of near-term issues as the company reported earnings above consensus and raised the lower end of its full-year earnings per share guidance. After factoring in these latest results, we are reiterating our $210 fair value estimate and wide economic moat rating for the pharmaceutical distributor.
- GlobeNewswire•15 days ago
Research Report Identifies Deckers Outdoor, Navient, Phillips 66, BioMarin Pharmaceutical, McKesson, and Equity Residential with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•16 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claim On Behalf of Investors of McKesson Corporation - MCK
Pomerantz LLP is investigating claims on behalf of investors of McKesson Corporation (“McKesson” or the “Company”) (NYSE: MCK). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On this news, McKesson’s stock price fell $12.55 per share, or roughly 8.3%, to close at $138.55 per share on January 26, 2017.
- GlobeNewswire•16 days ago
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against McKesson Corporation (MCK) and Lead Plaintiff Deadline: December 26, 2018
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against McKesson Corporation (“McKesson” or the “Company”) (MCK) on behalf of shareholders who purchased or otherwise acquired McKesson securities between October 24, 2013 and January 25, 2017, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.
- Simply Wall St.•19 days ago
Should You Worry About McKesson Corporation’s (NYSE:MCK) CEO Pay?
John Hammergren has been the CEO of McKesson Corporation (NYSE:MCK) since 2001. First, this article will compare CEO compensation with compensation at other large companies. After that, we will consider Read More...
- GlobeNewswire•19 days ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of McKesson Corporation (MCK)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of McKesson Corporation (“McKesson” or the “Company”) (MCK). The investigation concerns whether McKesson and certain of its officers and/or directors have violated federal securities laws.
- GlobeNewswire•19 days ago
Shareholder Alert - Bleichmar Fonti & Auld LLP Files Securities Class Action Lawsuit Against McKesson Corporation
Bleichmar Fonti & Auld LLP (“BFA”) announces that it has filed a class action lawsuit on behalf of a class (the “Class”) consisting of persons and entities that acquired McKesson Corporation (“McKesson” or the “Company”) (NYSE:MCK) common stock between October 24, 2013 and January 25, 2017, inclusive (the “Class Period”). The case was filed in the Northern District of California and is captioned Evanston Police Pension Fund v. McKesson, No. 3:18-cv-06525. McKesson delivers pharmaceutical and medical products and business services to retail pharmacies and institutional healthcare providers such as hospitals and health systems throughout North America and internationally.
Motley Fool•20 days agoMcKesson Corp (MCK) Q2 2019 Earnings Conference Call Transcript
MCK earnings call for the period ending September 30, 2018.
- Motley Fool•20 days ago
International Headwinds Keep Hammering McKesson
The drug distributor's foreign exposure remains a challenge.
- Zacks•20 days ago
McKesson (MCK) Beats Q2 Earnings, Misses Revenue Estimates
McKesson's (MCK) Q2 results benefit from solid performance in the Medical-Surgical Solutions segment.
- Zacks•20 days ago
McKesson (MCK) Surpasses Q2 Earnings Estimates
McKesson (MCK) delivered earnings and revenue surprises of 9.76% and -0.90%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
